Table 3.

Meta-Analysis of Standard-Dose NOACs vs Warfarin in RCTs³⁹

	Asians (n = 8,928)	Non-Asians (n = 64,033)	P Value for Interaction
Efficacy endpoints
Stroke/SE	0.65 (0.52-0.83)	0.85 (0.77-0.93)	0.045
Ischemic stroke	0.89 (0.87-1.17)	0.95 (0.84-1.06)	0.673
Hemorrhagic stroke	0.32 (0.19-0.52)	0.56 (0.44-0.70)	0.046
Myocardial infarction	0.97 (0.59-1.58)	0.98 (0.82-1.12)	0.977
All-cause death	0.80 (0.65-0.98)	0.91 (0.86-0.97)	0.219
Safety endpoints
Major bleeding	0.57 (0.44-0.74)	0.89 (0.76-1.04)	0.004
Intracranial hemorrhage	0.33 (0.22-0.50)	0.52 (0.42-0.64)	0.059
Gastrointestinal bleeding	0.79 (0.48-1.31)	1.44 (1.12-1.85)	0.041

Values are HR (95% CI).

NOAC = non-vitamin K antagonist oral anticoagulant; RCT = randomized controlled trial; SE = systemic embolization.